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Abstract Extracellular matrix remodeling and degradation are
of great importance in both physiological and pathological
situations. Matrix metalloproteinases (MMPs) and their natural
occurring inhibitors ^ tissue inhibitors of metalloproteinases
(TIMPs) ^ are involved in matrix turnover. Among the TIMPs
there is only little specificity for inhibiting individual MMPs. In
this report we describe the mutational analysis of the interaction
of human TIMP-4 with several MMPs. The effects of different
substitutions of residue 2 (Ser2) in the inhibitory domain of
TIMP-4 were determined by kinetic measurements. Size, charge
and polarity of residue 2 in the TIMP structure are key factors in
MMP inhibition. ß 2001 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
The matrix metalloproteinases (MMPs), a group of zinc-
dependent metalloendopeptidases including collagenases,
gelatinases, stromelysins and membrane-type metalloprotein-
ases, play a pivotal role in the remodeling of the extracellular
matrix and are thus implicated in many physiological and
pathological processes concerning the connective tissue re-
modeling. By stoichiometric binding to MMPs, tissue inhib-
itors of metalloproteinases (TIMPs) mediate MMP activity
and activation [1^4]. Currently, four members of the human
TIMP family are known, of those TIMP-4 has been identi¢ed
and cloned recently [5].
TIMPs are related in primary and secondary structure com-
prising 12 highly conserved cysteine residues forming six di-
sul¢de-bonded loops. TIMP-1, -2 and -4 are secreted proteins
and are found in various body £uids and tissues. TIMP-3 is
unique in that it appears bound to compounds of the extra-
cellular matrix [6,7].
Besides their high degree of homology in the amino acid
sequence especially in the ¢rst N-terminal amino acids, TIMP-
4 and TIMP-2 show several similarities. They are non-glyco-
sylated proteins and bind in a similar manner to human pro-
gelatinase A [8]. The e¡ect of TIMP-4 on growth of human
breast cancer cells in vivo was investigated by Wang et al. [9].
Cell invasiveness in vitro was inhibited by overexpression of
TIMP-4. When tumor cells transfected with TIMP-4 cDNA
were injected into nude mice tumor growth was signi¢cantly
reduced [9]. TIMP-4 is able to inhibit several active MMPs
[10,11].
TIMPs bind with their N-terminal domain into the entire
active site cleft of the MMPs. In the case of TIMP-2 there is a
considerable contribution of the AB L-hairpin loop to the
association [12]. The ¢ve N-terminal amino acids of TIMP
bind to the subsites of the MMP in a substrate-like manner,
forming ¢ve intermolecular hydrogen bonds. The so called sC-
connector loop including Val69/Gly71 (TIMP-1) or Ser68/Ala70
(TIMP-2) interacts in a substrate inverse manner [12,13]. A
relative small number of intermolecular contacts are found
between the C-terminal regions of the MMP and the TIMP.
The C-terminal region of TIMP shows a high degree of £ex-
ibility [13]. Superposition with the structure of full-length por-
cine MMP-1 revealed that the C-terminal domain of TIMP
and the hemopexin-like domain of the MMP would just touch
each other. Thus, the C-terminal domain contacts do not
contribute signi¢cantly to the TIMP binding of most MMPs
[13,14].
Recombinant TIMPs without C-terminal domain, the so
called inhibitory domains (idTIMPs), retain most of their ac-
tivity towards MMPs [15]. They have been used in various
inhibition studies and for analysis of MMP^TIMP interac-
tions to determine binding speci¢cities between TIMPs and
MMPs [16^19].
The N-terminal domain of TIMP-4 (residues 1^127, id-
TIMP-4) comprising three disul¢de-bonded loops folds inde-
pendently of the C-terminal domain. It contains the major site
of interaction with the catalytic domain (cd) of MMPs and is
therefore su⁄cient for inhibiting MMPs [11]. To examine the
role of residue 2 of TIMP-4 in complex with MMPs several
mutants of idTIMP-4 were constructed and expressed in the
methylotrophic yeast Pichia pastoris. The interaction of those
TIMP variants with MMPs was analyzed using kinetic mea-
surements.
2. Materials and methods
All chemicals used were purchased from Merck, Darmstadt, Ger-
many, or ICN, Eschwege, Germany. Oligonucleotides were from Life
Technologies, Karlsruhe, Germany. T4-DNA-ligase and TA-cloning
vector pGEMT were from Promega, Mannheim, Germany. The
P. pastoris expression kit was from Invitrogen, Groningen, The Neth-
erlands. All restriction enzymes were purchased from New England
Biolabs, Beverly, MA, USA. Chromatography materials were from
Pharmacia, Freiburg, Germany.
2.1. Construction and expression of idTIMP-4 mutants
With the appropiate oligonucleotides (Table 1) mutations and re-
striction sites were introduced into the idTIMP-4 cDNA by polymer-
0014-5793 / 01 / $20.00 ß 2001 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 9 8 7 - 8
*Corresponding author. Fax: (49)-521-106 6014.
E-mail address: harald.tschesche@uni-bielefeld.de (H. Tschesche).
Abbreviations: TIMP, tissue inhibitor of metalloproteinase; MMP,
matrix metalloproteinase; cd, catalytic domain; id, inhibitory domain
FEBS 25381 26-10-01
FEBS 25381 FEBS Letters 507 (2001) 285^287
ase chain reaction (PCR) using the Expand High ¢delity system
(Roche Diagnostics, Penzberg) and the pPICza-idTIMP-4 expression
vector as template [11]. The PCR product was subcloned into the TA-
cloning vector pGEMT, digested with XhoI and NotI, and inserted
into the pPICza vector. The correct insertion of the cDNA of id-
TIMP-4 in frame with the K-mating factor was con¢rmed by DNA
sequencing.
Electrocompetent cells of the P. pastoris strain X-33 were trans-
formed with the SacI-linearized plasmid DNA by electroporation ac-
cording to the manufacturer’s manual. The cells were plated at low
density on plates of yeast, peptone, dextrose and sorbitol containing
100 Wg/ml zeocin for selection of transformants. Transformants were
cultured in bu¡ered minimal glycerol medium for 24 h to an OD578 of
2^6 at 28‡C with vigorous shaking. Cells were harvested by centrifu-
gation at 2000Ug and resuspended in one volume expression medium
(bu¡ered minimal methanol). Expression was carried out at 28‡C for
6^7 days and was monitored by SDS^PAGE with silver staining. The
N-terminal amino acid sequence was veri¢ed by automated Edman
degradation [20].
2.2. Puri¢cation
Culture broth was centrifuged at 2000Ug to separate carefully from
cells and once again at 10 000Ug supernatant was ¢ltered and
(NH4)2SO4 was added to a ¢nal concentration of 1 M. Then the
solution was chromatographed on HIC material with 100 mM phos-
phate bu¡er and 1 M (NH4)2SO4 as starting bu¡er. The content of
(NH4)2SO4 was reduced stepwise to zero and ¢nally the protein was
eluted. After concentration by ultra¢ltration, dialysis against running
bu¡er (50 mM Tris^HCl pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 0.05%
Brij 35), and S200 FPLC size exclusion chromatography homogenous
protein could be obtained.
2.3. Kinetic measurements
ProMMP-9 was isolated from human plasma bu¡y coat as de-
scribed by Tschesche et al. [21]. Following activation by treatment
with trypsin at 37‡C for 30 min, activated gelatinase B was stored
for two additional hours at 0‡C. The recombinant cd of MMP-8 was
expressed in Escherichia coli as inclusion bodies, refolded, and puri¢ed
as described by Kleine et al. [22].
Enzyme concentrations were determined by active-site titration us-
ing Batimastat (BB-94) as inhibitor. All kinetic measurements were
performed in £uorimetry assay bu¡er (FA bu¡er; 5 mM Tris^HCl pH
7.5, 100 mM NaCl, 5 mM CaCl2, 0.05% PEG-6000) at 25‡C. MMP
and idTIMP-4 were preincubated at 25‡C in 100 Wl FA bu¡er for 30
min and then diluted with FA bu¡er containing substrate to a ¢nal
volume of 200 Wl. Enzyme activity was quanti¢ed by measuring the
rate of hydrolysis of the quenched £uorescent substrate (7-methoxy-
coumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitro-phenyl]-L-2,3-
diamino-propionyl)-Ala-Arg-NH2) using the plate reader Spectra-Fluor
Plus (Tecan, Austria) with excitation at 330 nm and emission at 405
nm with the gain set to 155. Each measurement was done in triplicate.
The degree of inhibition was determined for each inhibitor concen-
tration by plotting the steady state rates against the concentration of
inhibitor. Using the GraFit 4.0 software (Erithacus Software Limited)
a four parameter logistic ¢t to the dose^response data was employed
to calculate the corresponding IC50 values.
Assuming competitive inhibition Ki values were calculated for each
enzyme based on known Km values, which were determined at iden-
tical conditions [11] according to the equation described by Copeland
et al. [23] :
K i  IC503Et=2=1 S=Km:
3. Results and discussion
In complexes with MMPs TIMPs bind with their ¢ve
N-terminal residues to the active site cleft in a substrate-like
manner. A key feature of the protein^protein interface is the
bidentate coordination of the catalytic zinc of the MMP by
the K-amino and the carbonyl groups of the N-terminal cys-
teine of the TIMP molecule. The Thr/Ser side-chain of the
second residue extends into the SP1 pocket of the cognate
MMP. The Ser2 side-chain hydroxyl of TIMP-2 is hydro-
gen-bonded to the other carboxylate oxygen of the catalytic
Glu of the MMP displacing a water molecule from the active
site that normally plays an essential role in catalysis [12].
Therefore this residue is important for inhibiting MMPs.
Analysis of its function in complexes of idTIMP-4 and
MMPs is possible by substitution of this residue and deter-
mining the dissociation constants of these TIMP variants in
complexes with MMPs.
The mutations for the exchange of residue 2 were intro-
duced into the cDNA of idTIMP-4 by PCR using the id-
TIMP-4 expression vector as template. After successful trans-
formation of P. pastoris strain X-33 the expression of a 14.6
kDa protein could be detected after 3 days reaching a max-
imum at day 7 (Fig. 1). We were not able to express idTIMP-4
Ser2CPro. This substitution seems to be incompatible with
the TIMP structure, as proline is an imino acid. After several
puri¢cation steps including hydrophobic interaction chroma-
tography and size exclusion chromatography using a S200
column the homogenous protein was obtained and analyzed
by SDS^PAGE and N-terminal sequencing.
Using the quenched £uorescent substrate (7-methoxycou-
marin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitro-phenyl]-L-
2,3-diamino-propionyl)-Ala-Arg-NH2) MMP activities were
measured [24]. cdMMP-8 and MMP-9 were preincubated
with di¡erent concentrations of idTIMP-4 mutants and then
diluted with substrate-containing bu¡er to reach ¢nal concen-
trations of 0.8 nM (cdMMP-8) and 1.6 nM (MMP-9) and an
enzyme:substrate ratio of at least 1:1000. The remaining
Table 1
Primer sequences for the introduction of mutations in idTIMP-4
cDNA, codon exchanges are marked by bold characters
idTIMP-4 variant Primer sequence
idTIMP-4 Ser2 5P-CTCGAGAAAAGATGCAGCTGCGCCCCGGCG-3P
idTIMP-4
Ser2CGly
5P-CTCGAGAAAAGATGCGGCTGCGCCCCGGCG-3P
idTIMP-4
Ser2CAla
5P-CTCGAGAAAAGATGCGCCTGCGCCCCGGCG-3P
idTIMP-4
Ser2CGlu
5P-CTCGAGAAAAGATGCGAATGCGCCCCGGCG-3P
idTIMP-4
Ser2CAsp
5P-CTCGAGAAAAGATGCGACTGCGCCCCGGCG-3P
idTIMP-4
Ser2CPro
5P-CTCGAGAAAAGATGCCCCTGCGCCCCGGCG-3P
idTIMP-4 rev 5P-ATATAGCGGCCGCCTAGGGCTGAACGATGTCA-3P
Fig. 1. Expression of idTIMP-4 Ser2CGly (6). Analysis of P. pas-
toris culture supernatants by tricine^PAGE. Lane 1: LMW marker,
lanes 3^10: days 0^7 of expression.
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MMP activity was measured and plotted against the inhibitor
concentration. The calculated Ki values are shown in Table 2.
The exchange of residue 2 in TIMP-4 leads to an inhibitor
with altered speci¢cities. Whereas the wild type TIMP-4
shows a slight preference for collagenase-2 (MMP-8) the mu-
tants obviously bind tighter to gelatinase B (MMP-9). All
mutants of idTIMP-4 are inhibitors of lower a⁄nity to the
analyzed MMPs. The idTIMP-4 Ser2CGly is the weakest
inhibitor for the analyzed MMPs. The absence of a side-chain
in this mutant results in the loss of a major fraction of free
binding energy. Concentrations of 30 WM neither inhibited
MMP-8 nor MMP-9 more than 30%. Therefore Ki values
could not be determined for this variant.
Thus, the substitution of Ser by Gly results in a protein that
is inactive as inhibitor. The side-chain of residue 2 is therefore
a second marker of binding capacity. A methyl group as side-
chain is su⁄cient to recover inhibitory activity as was clearly
shown by the use of the alanine substitution. Charged amino
acids like aspartate and glutamate also reduce the TIMP/
MMP a⁄nity signi¢cantly. Besides the polarity of the amino
acid the steric consequence of the large side-chain seems to
play an important role. Compared to other MMPs, the SP1
pocket of collagenase-2 is of medium size because Arg243 of
the speci¢city loop extends into this pocket. In contrast the
SP1 pocket of gelatinase B is believed to be deep and narrow,
so that the e¡ects of polar or bulky substituents are of lower
in£uence [25,26]. Several studies concerning amino acid ex-
changes in TIMP-1 and TIMP-2 resulted in comparable var-
iations of binding speci¢cities [18,19]. Meng et al. analyzed the
in£uence of residue 2 in idTIMP-1 for inhibition of MMP-1,
-2 and -3 and came to the result that gelatinase A binds mu-
tants of idTIMP-1 with polar substituents in position 2 tighter
than does collagenase-1 [18]. The experiments of Butler et al.
showed a clear preference of idTIMP-2 mutants containing
amino acids with polar or bulky side-chains as residue 2 to
other MMPs than collagenase-3 [19]. So the size and the shape
of the SP1 pocket of the cognate MMP and the nature of the
residue 2 of TIMP are of clear in£uence for the inhibition
mechanism.
The ability of TIMP to displace solvent molecules in a free
MMP depends on the capacity to interact with hydroxyl
groups. This is the major determinant of a high a⁄nity and
therefore substituents like serine (see TIMP-2 and TIMP-4) or
threonine (see TIMP-1 and TIMP-3) are favorable and con-
served amino acids at this position. There is a clear structure^
function relationship of these amino acids for the inhibition of
the cognate MMPs.
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Table 2
Results of kinetic measurements
Tested idTIMP cdMMP-8 (0.8 nM)
Ki (nM)
MMP-9 (1.6 nM)
Ki (nM)
idTIMP-4 Ser2 9.7 14.5
idTIMP-4 Ser2CGly n.m. n.m.
idTIMP-4 Ser2CAla 1039.3 473.5
idTIMP-4 Ser2CGlu 979.3 431.5
idTIMP-4 Ser2CAsp 2667.6 1132.8
idTIMP-4 Ser2CPro n.d. n.d.
Determination of Ki values. Concentrations of MMPs were deter-
mined by active-site titration with Batimastat (S.D. were less than
10%). n.m. = no useful measurement results. n.d. = not determined.
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